Graham Cooper
Président chez KEZAR LIFE SCIENCES, INC.
Fortune : - $ au 30/04/2024
Profil
Graham K.
Cooper is currently the Chairman at Kezar Life Sciences, Inc. and an Independent Director at Beam Therapeutics, Inc. He previously served as the Executive Chairman at Applied Molecular Transport, Inc. from 2022 to 2023.
He was also the Director of Health Care Investment Banking at Deutsche Bank Securities, Inc. from 1997 to 2006.
Additionally, he held the position of Independent Director at Celladon Corp.
from 2013 to 2016 and at Unity Biotechnology, Inc. from 2017 to 2022.
Mr. Cooper was the Chief Financial Officer & EVP-Business Development at Geron Corp.
in 2012 and the Chief Financial Officer, Treasurer & Senior VP at Orexigen Therapeutics, Inc. from 2006 to 2011.
He also served as the CFO, CAO, Head-Investor & Media Relations at Receptos LLC from 2014 to 2015.
Mr. Cooper started his career as an Accountant at Deloitte & Touche LLP from 1992 to 1995.
He holds an undergraduate degree from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BEAM THERAPEUTICS, INC.
-.--% | 31/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
KEZAR LIFE SCIENCES INC
-.--% | 01/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Graham Cooper
| Sociétés | Poste | Début |
|---|---|---|
| KEZAR LIFE SCIENCES, INC. | Président | 12/05/2022 |
| BEAM THERAPEUTICS INC. | Directeur/Membre du Conseil | 10/10/2019 |
Anciens postes connus de Graham Cooper
| Sociétés | Poste | Fin |
|---|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Président | 08/03/2023 |
| UNITY BIOTECHNOLOGY, INC. | Directeur/Membre du Conseil | 25/05/2022 |
| ASSEMBLY BIOSCIENCES, INC. | Directeur Financier/CFO | 01/04/2019 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/03/2016 |
| RECEPTOS INC | Directeur Financier/CFO | 27/08/2015 |
Formation de Graham Cooper
| University of California, Berkeley | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| GERON CORPORATION | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| BEAM THERAPEUTICS INC. | Health Technology |
| APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Deutsche Bank Securities, Inc.
 Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve. | Finance |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Bioniz Therapeutics, Inc.
 Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Commercial Services |